Becton, Dickinson and Company (NYSE:BDX) Announces Earnings Results

Becton, Dickinson and Company (NYSE:BDX) issued its quarterly earnings results on Thursday. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.77 by $0.04, RTT News reports. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period last year, the business posted $3.42 earnings per share. The firm’s revenue was up 6.9% compared to the same quarter last year. Becton, Dickinson and Company updated its FY 2025 guidance to 14.250-14.600 EPS and its FY25 guidance to $14.25-14.60 EPS.

Becton, Dickinson and Company Price Performance

Shares of BDX stock traded down $9.06 during trading hours on Thursday, hitting $231.00. 1,620,127 shares of the company’s stock were exchanged, compared to its average volume of 1,380,382. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $257.58. The stock has a market cap of $66.77 billion, a price-to-earnings ratio of 49.40, a price-to-earnings-growth ratio of 1.76 and a beta of 0.43. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The stock’s 50-day moving average is $237.53 and its 200-day moving average is $235.16.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be given a $1.04 dividend. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a yield of 1.80%. Becton, Dickinson and Company’s payout ratio is presently 78.19%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI boosted their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Raymond James reduced their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Stifel Nicolaus raised their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.